This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.


Efficacy and Safety of Weekly Treatment With Enteric-Coated Fluoxetine in Patients With Major Depressive Disorder

Timothy G. Dinan, MD, PhD

Published: January 8, 2001

Article Abstract

A new formulation of fluoxetine has been developed that is intended to allow for weekly dosingduring the long-term treatment of depression. This 90-mg enteric-coated formulation of fluoxetinewas compared with 20-mg daily fluoxetine and placebo during a 25-week continuation treatment periodin a study of 501 depressed patients who had responded to acute treatment with 20-mg dailyfluoxetine. Both active drug formulations were statistically superior to placebo in maintaining theacute treatment response and prolonging the time to relapse. Patients with high baseline anxiety respondedsimilarly to the 90-mg weekly and 20-mg daily fluoxetine treatments. In addition, the 90-mgweekly fluoxetine dose had a safety profile similar to that of both daily fluoxetine dosing and placebo.The once-weekly fluoxetine formulation provides an effective and tolerable treatment option for patientsrequiring extended depression therapy.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 62

Quick Links: